NASDAQ$AYTU
Aytu BioScience Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Aytu BioPharma reported results for the first quarter of fiscal 2024, featuring a net revenue of $22.1 million and adjusted EBITDA of $2.2 million.
Aytu BioPharma reported a decrease in total net revenue to $22.1 million compared to $27.7 million in the previous year, primarily due to the wind down of the Consumer Health segment. The Rx segment's net revenue was $17.8 million, with ADHD product revenue increasing by 31%. The company reported a net loss of $8.1 million, impacted by a $5.9 million loss on derivative warrant liabilities.
- Total net revenue was $22.1 million, a decrease from $27.7 million year-over-year, mainly due to the planned wind down of the Consumer Health segment.
- ADHD product net revenue increased by 31% to $15.1 million compared to $11.6 million in the prior year.
- The Company’s Rx segment net revenue was $17.8 million compared to $18.7 million in the year-ago quarter.
- Cash and cash equivalents totaled $20.0 million as of September 30, 2023.
Headline financials
Revenue & EPS history
Aytu BioScience · Revenue · Quarterly
$22.1M
Revenue by segment
Aytu BioScience · $210K total across 1 segment · Q4 2023
- Other$210K-42.6%100.0%
Forward guidance
Aytu BioPharma is focusing on its Rx segment and winding down its Consumer Health segment to drive long-term shareholder value. The company expects to sell through the remaining Consumer Health inventory, resulting in approximately neutral Adjusted EBITDA for the segment in fiscal 2024.
Tailwinds
- Ramping up manufacturing at contract manufacturer.
- Focusing on growth and profitability in Rx segment.
- Expecting normalization of unit shipments in Pediatrics.
- Implementing strategies to deepen Pediatrics prescriptions.
- Exploring possible monetization opportunities for consumer health brands.
Headwinds
- Winding down Consumer Health segment.
- Impacted by payor changes in Pediatrics.
- Impacted by timing of customer ordering in Pediatrics.
- Suspension of pipeline clinical development programs.
- Experiencing ADHD stimulant supply disruptions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.0%
Avg return
Earnings day
-4.9%
Avg return
5 days after
-7.0%
Avg return
30 days after
19%
12 / 64 earnings
Positive
+91.7%
Q3 2025
Best reaction
-31.0%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -0.4% | -9.7% | -4.9% | |
| Q2 2026 | -3.3% | -11.8% | -4.4% | |
| Q1 2026 | -13.1% | -2.9% | +11.7% | |
| Q4 2025 | -20.1% | -31.9% | -9.6% | |
| Q3 2025 | +91.7% | +50.4% | +44.4% | |
| Q2 2025 | -0.7% | +0.7% | -13.7% | |
| Q1 2025 | -10.9% | -8.0% | -17.2% | |
| Q4 2024 | -2.9% | -3.3% | -11.1% | |
| Q3 2024 | -10.8% | -7.2% | -14.2% | |
| Q2 2024 | +4.3% | +6.0% | -4.0% | |
| Q1 2024 | -14.2% | -14.2% | +6.7% | |
| Q4 2023 | +61.8% | +76.4% | +60.6% | |
| Q3 2023 | -12.8% | -16.6% | -24.2% | |
| Q2 2023 | -5.1% | -9.9% | -29.8% | |
| Q1 2023 | +5.3% | +21.1% | +10.5% | |
| Q4 2022 | +0.0% | +0.0% | -10.5% | |
| Q3 2022 | +5.8% | +7.7% | -5.8% | |
| Q2 2022 | +5.6% | +4.8% | -13.5% | |
| Q1 2022 | -10.5% | -18.2% | -36.0% | |
| Q4 2021 | -3.7% | -0.7% | -19.9% | |
| Q3 2021 | +0.7% | +5.0% | -5.9% | |
| Q2 2021 | -5.3% | -9.0% | -5.1% | |
| Q1 2021 | -4.9% | -8.8% | -38.4% | |
| Q4 2020 | -14.1% | -16.3% | -23.0% | |
| Q3 2020 | -7.7% | -13.0% | -13.0% | |
| Q2 2020 | +2.6% | +2.6% | +49.4% | |
| Q1 2020 | -21.7% | -28.3% | -14.2% | |
| Q4 2019 | -10.9% | -16.7% | -18.8% | |
| Q3 2019 | -6.7% | -14.8% | -21.1% | |
| Q2 2019 | -22.0% | -21.2% | +6.8% | |
| Q1 2019 | -22.0% | -21.2% | +6.8% | |
| Q4 2018 | -2.8% | -13.0% | -10.2% | |
| Q3 2018 | +24.2% | +12.1% | +21.2% | |
| Q2 2018 | -31.0% | -54.5% | -86.6% | |
| Q1 2018 | -14.8% | -22.6% | -29.0% | |
| Q4 2017 | -3.0% | +3.8% | +7.8% | |
| Q3 2017 | -4.0% | -9.3% | -6.7% | |
| Q2 2017 | -4.9% | -9.8% | -16.7% | |
| Q1 2017 | +11.6% | +5.4% | +16.1% | |
| Q4 2016 | +5.3% | +2.7% | -13.1% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | +7.7% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — | |
| Q4 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro